FIELD: medicine, pharmacy. SUBSTANCE: pharmaceutical composition has a compound that is able to inhibit calmodulin binding with cytoskeleton protein as an active component and a drug has a compound inhibiting cytoskeleton protein catabolism as an active component. Composition has 1-1000 mg of 3-{ 2-[4-(3-chloro-2-methylphenyl)- -1-piperazinyl]ethyl}-5,6-dimethoxy-1-(3,4-dimethoxybenzyl)- -1H-indazole or 3-{2-[4-(3-chloro-2-methylphenyl)-1-piperazinyl]- -ethyl}-5,6-dimethoxy-1-(4-imidazolylmethyl)-1H-indazole and pharmaceutically acceptable carriers. Composition and drug are used for treatment of patients with cerebral disorders, brain cell apoptosis inhibition induced by the brain ischemia. Invention provides a possibility of treatment of patients with different brain sicknesses and their complications and for relapse prophylaxis of these sicknesses. EFFECT: enhanced effectiveness of the composition. 7 cl, 3 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| CRYSTALLINE 3[-2[4-(3-CHLORO-2-METHYLPHENYL)-1- PIPERAZINYL]ETHYL]-5,6-DIMETHOXY-1-[4-IMIDAZOLYLMETHYL]- 1H-INDAZOLE DEHYDROCHLORIDE AND 3,5-HYDRATE THEREOF, AND METHODS OF PREPARATION THEREOF | 1995 |
|
RU2152941C1 |
| PIPERAZINE DERIVATIVES | 1994 |
|
RU2124511C1 |
| PROTECTIVE AGENT FOR NEURAL RETINA CELLS CONTAINING INDAZOLE DERIVATIVES AS ACTIVE INGREDIENT | 2006 |
|
RU2392938C2 |
| PIPERAZINE-CYCLODEXTRIN COMPLEX AND MEDICINAL AGENT CONTAINING INDICATED COMPLEX | 1998 |
|
RU2216549C2 |
| PYRIDONE CARBOXYLIC ACID DERIVATIVES AND COMPOSITION BASED ON THEREOF | 1993 |
|
RU2100351C1 |
| N-(2-THIAZOLYL)AMIDE DERIVATIVES AS GSK-3 INHIBITORS | 2007 |
|
RU2429237C2 |
| DIAZABICYCLOALKENE DERIVATIVES AND PHARMACEUTICAL COMPOSITION | 1993 |
|
RU2126008C1 |
| SALT OF PYRAZOLOQUINOLINE DERIVATIVE AND CRYSTAL THEREOF | 2014 |
|
RU2655171C2 |
| 2-PROPEN-1-ONS AS HSP-70 INDUCTORS | 2005 |
|
RU2341522C2 |
| AROMATIC AMIDINE DERIVATIVE AND PHARMACEUTICAL COMPOSITION | 1992 |
|
RU2139851C1 |
